AIM:To determine the effects of RNAi-mediated inhibition of the growth hormone receptor(GHR)gene on tumors and colon cancer cells in vivo.METHODS:Construction of a eukaryotic vector for human GHR expression,the pcDNA 6.2-GW/EmGFPsmall interfering RNAs(siRNAs)-GHR plasmid,was used to inhibit GHR expression.Thirty-six BALB/c nude mice were randomly divided into groups and treated with normal saline(NS),recombinant plasmid(G2),growth hormone(GH),5-fluorouracil(FU),G2+FU or G2+FU+GH.Each nude mouse was subcutaneously inoculated with 1×107human colon cancer SW480 cells;the nude mice were weighed before inoculation and on the 2nd,5th,8th,11th,14thand 17thday after inoculation.All nude mice were sacrificed after 17 d.Each subcutaneous tumor was removed and studied.Tumor volume was measured on the 5th,8th,11th,14thand 17thday after inoculation.The expression of GHR protein in the tumor tissue was detected by Western blotting analysis,and the differences in GHR mRNA expression in the tumor tissue were detected by real-time quantitative reverse transcription-polymerase chain reaction.RESULTS:Compared to the control group,the weights of the inoculated nude mice on the 17thday after inoculation were:G2:21.60±0.71 g,GH:21.64±0.45 g,FU:18.94±0.47 g,FU+G2:19.40±0.60 g,G2+FU+GH:21.04±0.78 g vs NS:20.68±0.66 g,P<0.05;the tumor volumes after the subcutaneous inoculation were:G2:9.71±3.82 mm3,FU:11.54±2.42mm3,FU+G2:11.42±1.11 mm3,G2+FU+GH:10.47±1.02 mm3vs NS:116.81±10.61 mm3,P<0.05.Compared to the GH group,the tumor volumes were significantly decreased in the experimental groups.The GHR protein expression(G2:0.39±0.02,FU:0.40±0.02,FU+G2:0.38±0.01,G2+FU+GH:0.39±0.01 vs NS:0.94±0.02,P<0.05)and the GHR mRNA expression(G2:14.12±0.10,FU:15.15±0.44,FU+G2:16.46±0.27,G2+FU+GH:15.37±0.57 vs NS:12.63±0.14,P<0.05)were significantly decreased and increased,respectively,in the experimental groups.CONCLUSION:Inhibition of GHR in human colon cancer SW480 cells resulted in anti-tumor effects in nude mice. AIM: To determine the effects of RNAi-mediated inhibition of the growth hormone receptor (GHR) gene on tumors and colon cancer cells in vivo. METHODS: Construction of a eukaryotic vector for human GHR expression, the pcDNA 6.2-GW / EmGFPsmall interfering RNAs (siRNAs) - GHR plasmid, was used to inhibit GHR expression. Six-six BALB / c nude mice were randomly divided into groups and treated with normal saline (NS), recombinant plasmid (G2), growth hormone fluorouracil (FU), G2 + FU or G2 + FU + GH. Each nude mouse was subcutaneously inoculated with 1 × 107 human colon cancer SW480 cells; the nude mice were weighed before inoculation and on the 2nd, 5th, 8th, 11th, 14thand 17thday after inoculation. All nude mice were sacrificed after 17 d. Each subcutaneous tumor was removed and studied. Volume volume was measured on the 5th, 8th, 11th, 14 thand 17thday after inoculation. The expression of GHR protein in the tumor tissue was detected by Western blotting analysis, and the differences in GHR mRNA expression in the tumor tis sue were detected by real-time quantitative reverse transcription-polymerase chain reaction .RESULTS: Compared to the control group, the weights of the inoculated nude mice on the 17thday after inoculation were: G2: 21.60 ± 0.71 g, GH: 21.64 ± 0.45 g , FU: 18.94 ± 0.47 g, FU + G2: 19.40 ± 0.60 g, G2 + FU + GH: 21.04 ± 0.78 g vs NS: 20.68 ± 0.66 g, P <0.05; the tumor volumes after the subcutaneous inoculation were: 9.71 ± 3.82 mm3, FU: 11.54 ± 2.42 mm3, FU + G2: 11.42 ± 1.11 mm3, G2 + FU + GH: 10.47 ± 1.02 mm3 vs NS: 116.81 ± 10.61 mm3, P <0.05.Compared to the GH group, the tumor were significantly decreased in the experimental groups. The GHR protein expression (G2: 0.39 ± 0.02, FU: 0.40 ± 0.02, FU + G2: 0.38 ± 0.01, G2 + FU + (G2: 14.12 ± 0.10, FU: 15.15 ± 0.44, FU + G2: 16.46 ± 0.27, G2 + FU + GH: 15.37 ± 0.57 vs NS: 12.63 ± 0.14, P <0.05) were significantly decreased and increased, respectively, in the experimental groups. CONCLUSION: Inhibition of GHR in human colon cancer SW480 cells resulted in anti- tumor effects in nudemice.